Gonadal function and fertility after Hodgkin lymphoma treatment with nivolumab-AVD in the 2 GHSG NIVAHL trial
Autor/innen
- Anne Sophie Robertz
- Ina Bühnen
- Julia Meissner
- Karolin Trautmann-Grill
- Peter Herhaus
- Teresa Halbsguth
- Valdete Schaub
- Andrea Kerkhoff
- Stephan Mathas
- Matthias Bormann
- Andreas Dickhut
- Christian P. Jaworek
- Michael Fuchs
- Carsten Kobe
- Christian Baues
- Peter Borchmann
- Bastian von Tresckow
- Karolin Behringer
- Paul J. Bröckelmann
Journal
- Blood
Quellenangabe
- Blood 147 (25): 3118-3121
Zusammenfassung
In 82 patients with classic Hodgkin lymphoma, stable gonadal hormone levels were observed up to 24 months after nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) first-line treatment. These findings suggest preserved gonadal function and fertility after 4×N-AVD. The trial was registered at www.clinicaltrials.gov as NCT03004833.